<DOC>
	<DOCNO>NCT02065570</DOCNO>
	<brief_summary>This study evaluate high versus standard adalimumab dose regimen induction maintenance therapy subject moderately severely active Crohn 's Disease evidence mucosal ulceration .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety Two Drug Regimens Subjects With Moderate Severe Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Diagnosis Crohn 's disease ( CD ) least 90 day , confirm endoscopy Screening Period . Active CD Crohn 's Disease Activity Index ( CDAI ) despite treatment oral corticosteroid and/or immunosuppressant . Mucosal ulceration endoscopy . Subject ulcerative colitis indeterminate colitis . Subject surgical bowel resection past 6 month plan resection . Subjects ostomy ileoanal pouch . Subject symptomatic bowel stricture abdominal perianal abcess . Subject short bowel syndrome . Chronic recur infection active Tuberculosis ( TB ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Crohn 's Disease</keyword>
</DOC>